Skip to Content

Teva Pharmaceuticals Industries Limited

Company NameTeva Pharmaceuticals Industries Limited
Stock SymbolTEVA
Class PeriodOctober 29, 2015 to August 18, 2020
Lead Plaintiff Motion DeadlineOctober 23, 2020

On August 18, 2020, the U.S. Department of Justice (“DOJ”) announced that it had filed a complaint against Teva under the False Claim Act, alleging that, from 2007 through 2015, Teva paid certain foundations “with the intent and understanding that they would use Teva’s money to cover the Medicare co-pays of patients taking Copaxone.” The DOJ further stated that during this period “Teva raised the price of Copaxone from approximately $17,000 per year to over $73,000 per year.”


On this news, Teva’s American Depositary Receipt (“ADR”) price fell $1.11 per share, or over 9%, to close at $10.48 per ADR on August 18, 2020, thereby injuring investors.

Submit Your Information

If you suffered a loss on your Teva Pharmaceuticals Industries Limited investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd